Liquid biopsy: Tumor diagnosis and treatment monitoring in a blood test. Radmila Jankovic, PhD Institute for Oncology and Radiology of Serbia

Liquid biopsy: Tumor diagnosis and treatment monitoring in a blood test Radmila Jankovic, PhD Institute for Oncology and Radiology of Serbia Term “...
Author: Dustin Pierce
0 downloads 1 Views 3MB Size
Liquid biopsy: Tumor diagnosis and treatment monitoring in a blood test

Radmila Jankovic, PhD Institute for Oncology and Radiology of Serbia

Term “Liquid biopsy” stands for: 

Circulating tumor cells (CTCs)

Cell-free DNA (cfDNA)  Plasma  Serum  Other liquid material 



Exosomes

Circulating tumor cells (CTCs) 

etiology  disseminated cancer cells  cancer stem cells



rare cells in a dormant, nonproliferative state    

unaffected by chemotherapy unrecognized by the host immune system difficult to isolate advanced cancer has less then 10 CTCs per 7.5ml of blood

Origin of CTCs

(Paterlini-Brechot et al. Cancer Letters 2007. 253:180.)

Main approaches for CTC detection

Immunomagnetic Capture composite

CD45

control

cytokeratin

AntiEpCAM Ferrofluid

Anti CD45-APC

EpCAM Nucleus DAPI

Nucleus DAPI

CD45

CK AntiCK-PE

Circulating Tumor Cell

CellSearch™ System

DAPI

Leukocyte

Individual Cell Sorting with DEPArray™ Recovery

Parking

1. Inject, trap and image all cells 2. Move all cells of interest into Parking chamber 3. Move separately to Recovery chamber and flush

Main chamber

Features  Multiparametric image-based sorting  Single cell resolution  Small cell loads  Gentle on cells  No a priori thresholds  choose best cells  Sorting based on slow kinetics (10-100s minutes) possible

p. 7

In vivo isolation of circulating tumor cells from peripheral blood of cancer patients

Saucedo-Zeni N et al, Int J Oncol. 2012 Oct; 41(4): 1241–1250.

Microtube surface is coated with both E-selectin and antiepithelial antibodies (EpCAM or PSMA)

Halloysite Nanotube Protein G

E-Selectin-Fc Chimera Anti-EpCAM/PSMA mAb

Clinical relevance of CTCs in breast cancer Applications Prognosis

Monitor

Metastasis Drug Activity Cell culture Xenograft Model

Approaches Enumeration  Molecular characterization  DNA/RNA NGS Sequencing 

71%

53% 49%

50 45

47% 46% 45%

40%

40

35%

35

42% 38% 38%

32%

30

30% 29% 28%

26%

25 20

36%

34% 34% 34%

27% 24% 23% 23% 23% 23% 22% 21% 21% 21% 21% 20% 15%

15

CTC threshold (per 7.5 ml blood)

20

15

14

13

12

11

10

9

8

7

6

5

1%

4

0

3

5

16% 8%

8% 6%

2

10

13% 13%

3% 1%

1000

55

58%

55%

50

60

61%

100

65

healthy volunteers (n = 145) benign diseases (n = 200) cancer, baseline (n = 177) cancer, first follow-Up (n = 163)

40

70

30

75

1

% patients at or above the CTC threshold

Baseline enumeration in MBC

Beyond the enumeration: Is the CTC count relevant for development & progression of metastases?

The independent prognostic effect of CTC count on progression-free survival and overall survival. CTC count also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.

Beyond the enumeration: Is the CTC count relevant for therapy efficacy monitoring?

Study confirms the prognostic significance of CTCs in patients with MBC receiving first-line chemotherapy. For patients with persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternate cytotoxic therapy was not effective in prolonging OS.

Negative study?

Beyond the enumeration: Molecular characterization of CTCs Nat Genet 2013 Dec;45(12):1415-6. doi: 10.1038/ng.2831. The search for ESR1 mutations in breast cancer. Oesterreich S, Davidson NE

Term “Liquid biopsy” stands for: 

Circulating tumor cells (CTC)

Cell-free DNA (cfDNA)  Plasma  Serum  Other liquid material 



Exosomes

Origin of Circulating Tumour DNA (ctDNA) What is ctDNA?

 ctDNA is tumour DNA that has been shed into the bloodstream  ctDNA can be present in 0.01% - >90% of the total Cell Free DNA (cfDNA)

 The amount of ctDNA is related to the tumour burden and varies between patients with different clinical presentations

Diaz and Bardelli, 2014 Journal of Clincial Oncology 32

Clinical relevance of ctDNA

Applications: 





Tumor genotyping: Tissue versus liquid biopsy Monitoring tumor burden, therapeutic response and treatment Minimal residual disease monitoring and early detection

Approaches: PCR-based approaches Nested real-time PCR PARE ARMS-Scorpion PCR PAP-A amplification BEAMing Microfluidic digital PCR Droplet-based digital PCR NGS-based approaches Targeted deep sequencing Tam-Seq Safe-Seq CAPP-Seq Ion-AmpliSeqTM Whole exome sequencing Whole genome Sequencing 19

FFPE vs. ctDNA ctDNA Samples

FFPE Samples 

Problems with quality of DNA due to  fixation  Mixture of normal and tumour DNA   Some patients have no tumour  sample available  The sample represents the tumour at  one fixed time point 

ctDNA shed directly from tumour Extracted from the plasma component of whole blood Large fragment sizes possible Small quantities extracted ~ 30ng/ 5ml plasma Serial samples can be taken at various time points during the patient’s treatment

Isolation and processing of ctDNA

Blood sample taken

Sample spun down to isolate the plasma

Plasma is stored at -80ºc

ctDNA is extracted from the plasma using the QIAamp Circulating Nucleic Acid or some other commercial kit

Applications:: Next-generation sequencing Quantative PCR BEAMing Digital PCR

Major techical advantage compared to CTC

Possible problems? 

ctDNA is unstable: requires fast processing



Getting only 30ng of ctDNA per 5ml plasma extraction



The technique used must be sensitive enough to pick up the low level variants

Diaz and Bardelli, 2014 Journal of Clincial Oncology 32

ctDNA: methods What is Droplet Digital PCR?

Expensive equipment?

ctDNA for monitoring metastasis

This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer

ctDNA for monitoring drug resistance

Exome-wide analysis of circulating tumour DNA could complement current invasive biopsy approaches to identify mutations associated with acquired drug resistance in advanced cancers. Serial analysis of cancer genomes in plasma constitutes a new paradigm for the study of clonal evolution in human cancers.

ctDNA as biomarkers of microscopic residual disease after surgery?

Study demonstrates accurate mutation detection in tumor tissues using ddPCR, and that ptDNA can be detected in blood before and after surgery in patients with early-stage breast cancer. ptDNA could identifies patients at risk for recurrence, which could guide chemotherapy decisions for individual patients.

CTCs or ctDNA?

Complementary roles as cancer biomarkers!

Daniel A. Haber, and Victor E. Velculescu Cancer Discovery 2014;4:650-661 ©2014 by American Association for Cancer Research

Term “Liquid biopsy” stands for: 

Circulating tumor cells (CTC)

Cell-free DNA (cfDNA)  Plasma  Serum  Other liquid material 



Exosomes

Tumor signatures in the blood, Nature Biotechnology, 32, 2014

Thank you for you attention!

Suggest Documents